0.32
0.32 (-19.95%)
As of Dec 11, 2023
Evelo Biosciences, Inc. [EVLO]
Source:
Company Overview
Evelo Biosciences is discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. The target cells in the small intestine play a central role in governing human immune, metabolic and neurologic systems. We refer to this biology as the small intestinal axis, or SINTAX. We have built a platform to discover and develop novel oral medicines which target the small intestinal axis.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-577-0300 |
| Industry | manufacturing |
| CEO | Balkrishan Gill |
| Website | www.evelobio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-11.2 |
| Net Income | $-12.4 |
| Net Cash | $-31 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -29.1% |
| Profit as % of Stockholder Equity | 46.3% |
Management Effectiveness
| Return on Equity | 46.3% |
| Return on Assets | -59.9% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $20.6 |
| Total Liabilities | $47.3 |
| Operating Cash Flow | $-50.5 |
| Investing Cash Flow | $0.5 |
| Financing Cash Flow | $19 |
